News headlines about C R Bard (NYSE:BCR) have trended positive this week, according to Alpha One Sentiment. The research group, a subsidiary of Accern, identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. C R Bard earned a news sentiment score of 0.31 on Alpha One’s scale. Alpha One also assigned news headlines about the medical instruments supplier an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have effected Alpha One Sentiment’s scoring:

C R Bard (NYSE:BCR) traded up 0.46% on Friday, hitting $307.79. 191,714 shares of the stock traded hands. The firm has a market capitalization of $22.29 billion, a PE ratio of 39.17 and a beta of 0.63. The stock has a 50 day moving average of $280.57 and a 200 day moving average of $243.25. C R Bard has a 52 week low of $203.63 and a 52 week high of $309.16.

C R Bard (NYSE:BCR) last announced its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.22. The firm had revenue of $938.80 million during the quarter, compared to analyst estimates of $916.15 million. C R Bard had a net margin of 14.31% and a return on equity of 48.48%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the business posted $2.34 EPS. Equities research analysts anticipate that C R Bard will post $11.78 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, May 12th. Investors of record on Monday, May 1st were issued a dividend of $0.26 per share. The ex-dividend date was Thursday, April 27th. This represents a $1.04 dividend on an annualized basis and a yield of 0.34%. C R Bard’s dividend payout ratio is currently 14.77%.

BCR has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of C R Bard from a “buy” rating to a “hold” rating in a research note on Tuesday, March 28th. Jefferies Group LLC reaffirmed a “hold” rating and set a $237.00 target price on shares of C R Bard in a report on Monday, March 27th. Barclays PLC reaffirmed a “hold” rating and set a $245.00 target price on shares of C R Bard in a report on Sunday, January 29th. BMO Capital Markets reaffirmed a “buy” rating and set a $255.00 target price on shares of C R Bard in a report on Tuesday, April 11th. Finally, Morgan Stanley lowered shares of C R Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. Twelve investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $263.21.

COPYRIGHT VIOLATION NOTICE: “C R Bard (BCR) Receiving Favorable News Coverage, Report Shows” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/05/19/c-r-bard-bcr-receives-daily-news-impact-score-of-0-31-updated.html.

In related news, insider Jim C. Beasley sold 4,390 shares of the company’s stock in a transaction on Tuesday, February 21st. The shares were sold at an average price of $245.00, for a total transaction of $1,075,550.00. Following the completion of the sale, the insider now directly owns 26,625 shares in the company, valued at approximately $6,523,125. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Frank Lupisella, Jr. sold 3,622 shares of the company’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the sale, the vice president now owns 10,139 shares of the company’s stock, valued at $3,082,256. The disclosure for this sale can be found here. Corporate insiders own 0.97% of the company’s stock.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

5 Day Chart for NYSE:BCR

Receive News & Stock Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related stocks with our FREE daily email newsletter.